Epivir data

BCHXF announced that combination therapies using 3TC with AZT and a protease inhibitor can reduce the viral load in HIV infection to undetectable levels, as reported at the International Conference on AIDS in Vancouver.

In a trial with Merck's Crixivan indinavir, 97 patients received either 3TC plus AZT, indinavir alone, or the triple combination. HIV levels dropped to undetectable levels in 5 of 6 patients receiving the triple combination throughout the 44 weeks for which data are available. Median CD4 counts increased by 218 cells over baseline during this time. ...